COVID: Omicron BA 2 infection after vaccine can protect from BA 4/BA 5 jpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jpost.com Daily Mail and Mail on Sunday newspapers.
A new study that evaluated the effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the Omicron variant indicates that three doses could offer a sufficient level of protection from disease caused by the Omicron variant.
E-Mail
In a study evaluating the BioNTech-Pfizer COVID-19 vaccine s ability to neutralize the B.1.1.7 ( UK ) viral variant, researchers found no loss of immune protection compared to that against the original Wuhan reference strain. Their analysis was based on blood samples from 40 people who had received the BioNTech-Pfizer COVID-19 vaccine during clinical trials. The authors conclude their results show it is unlikely that the UK variant virus will escape . protection as mediated by this vaccine. In September 2020, the SARS-CoV-2 lineage B.1.1.7 was discovered in the United Kingdom. It subsequently increased in prevalence, showed enhanced transmissibility, and spread to other continents. The B.1.1.7 variant has a series of mutations in its spike (S) protein, which it uses to gain entry to host cells. Whether a virus with the large number of mutations found in the spike protein of lineage B.1.1.7 could be neutralized by the blood sera from people who had received the BioNTech-P